Pharmaceutical Combinations
AssigneeNovartis AG
InventorsDale Porter, Caroline Emery, Lujian Tan, Padmaja Yerramilli-Rao
Life of this patent
Estimating the term…
Abstract
A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
Claims23
A pharmaceutical combination comprising or consisting of:
- (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and
- (b) a mitogen activated protein kinase (MEK) inhibitor compound, or a pharmaceutically acceptable salt thereof.
(canceled)
(canceled)
(canceled)
A method for treating a proliferative disease, comprising the simultaneous, separate or sequential administration of a therapeutically effective amount of a PKC inhibitor compound, or a pharmaceutically acceptable salt thereof, in combination with at least one MEK inhibitor compound, or a pharmaceutically acceptable salt thereof, to a patient in need thereof having a proliferative disease.
A method for treating a proliferative disease, comprising the simultaneous, separate or sequential administration of a therapeutically effective amount of the PKC inhibitor compound 3-(1H-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-1H-pyrrole-2,5-dione or a pharmaceutically acceptable salt thereof, in combination with at least one MEK inhibitor compound selected from the group comprising 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide, (S)-5-fluoro-2-(2-fluoro-4-(methylthio)phenylamino)-N-(2-hydroxypropoxy)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide, PD0325901, PD-184352, RDEA119, GSK1120212, XL518, AS-701255, AS-701173, AS703026, RDEA436, E6201, R04987655, JTP-74057, RG7167, or RG7420 or a pharmaceutically acceptable salt thereof, to a patient in need thereof having a proliferative disease.
A combined preparation comprising (a) one or more unit dosage forms of a PKC inhibitor compound 3-(1H-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-1H-pyrrole-2,5-dione or a pharmaceutically acceptable salt thereof, and (b) one or more unit dosage forms of a MEK inhibitor compound or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.